73 Year Old Man C.E Case Study Emphysema

  • Brooks M. FDA Clears Olodaterol (Striverdi Respimat) for COPD. Medscape Medical News. Available at http://www.medscape.com/viewarticle/829248. Accessed: August 4, 2014.

  • Maclay JD, Rabinovich RA, MacNee W. Update in chronic obstructive pulmonary disease 2008. Am J Respir Crit Care Med. 2009 Apr 1. 179(7):533-41. [Medline].

  • Casanova C, Cote C, Marin JM, Pinto-Plata V, de Torres JP, Aguirre-Jaime A, et al. Distance and oxygen desaturation during the 6-min walk test as predictors of long-term mortality in patients with COPD. Chest. 2008 Oct. 134(4):746-52. [Medline].

  • [Guideline] Global strategy for diagnosis, management, and prevention of COPD: 2016. Global Initiative for Chronic Obstructive Lung Disease. Available at http://goldcopd.org/gold-reports/ . Accessed: May 7, 2016.

  • Feghali-Bostwick CA, Gadgil AS, Otterbein LE, Pilewski JM, Stoner MW, Csizmadia E. Autoantibodies in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. Jan 15 2008. 177(2):156-63.

  • Houben JM, Mercken EM, Ketelslegers HB, Bast A, Wouters EF, Hageman GJ. Telomere shortening in chronic obstructive pulmonary disease. Respir Med. 2009 Feb. 103(2):230-6. [Medline].

  • Morissette MC, Vachon-Beaudoin G, Parent J, Chakir J, Milot J. Increased p53 level, Bax/Bcl-x(L) ratio, and TRAIL receptor expression in human emphysema. Am J Respir Crit Care Med. 2008 Aug 1. 178(3):240-7. [Medline].

  • Hodge S, Hodge G, Jersmann H, Matthews G, Ahern J, Holmes M, et al. Azithromycin improves macrophage phagocytic function and expression of mannose receptor in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008 Jul 15. 178(2):139-48. [Medline].

  • Casanova C, de Torres JP, Navarro J, Aguirre-Jaime A, Toledo P, Cordoba E, et al. Microalbuminuria and hypoxemia in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010 Oct 15. 182(8):1004-10. [Medline].

  • Ofir D, Laveneziana P, Webb KA, Lam YM, O'Donnell DE. Mechanisms of dyspnea during cycle exercise in symptomatic patients with GOLD stage I chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008 Mar 15. 177(6):622-9. [Medline].

  • Belman MJ, Botnick WC, Shin JW. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1996 Mar. 153(3):967-75. [Medline].

  • O'Donnell DE, Lam M, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999 Aug. 160(2):542-9. [Medline].

  • Marin JM, Carrizo SJ, Gascon M, Sanchez A, Gallego B, Celli BR. Inspiratory capacity, dynamic hyperinflation, breathlessness, and exercise performance during the 6-minute-walk test in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001 May. 163(6):1395-9. [Medline].

  • O'Donnell DE, Fluge T, Gerken F, Hamilton A, Webb K, Aguilaniu B. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J. 2004 Jun. 23(6):832-40. [Medline].

  • Martinez FJ, de Oca MM, Whyte RI, Stetz J, Gay SE, Celli BR. Lung-volume reduction improves dyspnea, dynamic hyperinflation, and respiratory muscle function. Am J Respir Crit Care Med. 1997 Jun. 155(6):1984-90. [Medline].

  • Celli BR. Update on the management of COPD. Chest. 2008 Jun. 133(6):1451-62. [Medline].

  • Casanova C, Cote C, de Torres JP, Aguirre-Jaime A, Marin JM, Pinto-Plata V. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005 Mar 15. 171(6):591-7. [Medline].

  • Nagelmann A, Tonnov A, Laks T, Sepper R, Prikk K. Lung Dysfunction of Chronic Smokers with No Signs of COPD. COPD. 2011 Apr 22. [Medline].

  • Lamprecht B, McBurnie MA, Vollmer WM, Gudmundsson G, Welte T, Nizankowska-Mogilnicka E, et al. COPD in Never Smokers: Results From the Population-Based Burden of Obstructive Lung Disease Study. Chest. 2011 Apr. 139(4):752-763. [Medline].

  • Andersen ZJ, Hvidberg M, Jensen SS, Ketzel M, Loft S, Sorensen M, et al. Chronic obstructive pulmonary disease and long-term exposure to traffic-related air pollution: a cohort study. Am J Respir Crit Care Med. 2011 Feb 15. 183(4):455-61. [Medline].

  • Tashkin DP, Altose MD, Bleecker ER, Connett JE, Kanner RE, Lee WW, et al. The lung health study: airway responsiveness to inhaled methacholine in smokers with mild to moderate airflow limitation. The Lung Health Study Research Group. Am Rev Respir Dis. 1992 Feb. 145 (2 Pt 1):301-10. [Medline].

  • Crothers K, Butt AA, Gibert CL, Rodriguez-Barradas MC, Crystal S, Justice AC. Increased COPD among HIV-positive compared to HIV-negative veterans. Chest. 2006 Nov. 130(5):1326-33. [Medline].

  • Adams PF, Barnes PM, Vickerie JL. Summary health statistics for the U.S. population: National Health Interview Survey, 2007. Vital Health Stat 10. 2008 Nov. 1-104. [Medline].

  • Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet. 2007 Sep 1. 370(9589):741-50. [Medline].

  • Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J. 2006 Sep. 28(3):523-32. [Medline].

  • Foreman MG, Zhang L, Murphy J, et al. Early-Onset COPD is Associated with Female Gender, Maternal Factors, and African American Race in the COPDGene Study. Am J Respir Crit Care Med. 2011 May 11. [Medline].

  • Mintz ML, Yawn BP, Mannino DM, et al. Prevalence of airway obstruction assessed by lung function questionnaire. Mayo Clin Proc. 2011 May. 86(5):375-81. [Medline]. [Full Text].

  • Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004 Mar 4. 350(10):1005-12. [Medline].

  • Waschki B, Kirsten A, Holz O, et al. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest. 2011 Aug. 140(2):331-42. [Medline].

  • Abrams TE, Vaughan-Sarrazin M, Fan VS, Kaboli PJ. Geographic isolation and the risk for chronic obstructive pulmonary disease-related mortality: a cohort study. Ann Intern Med. 2011 Jul 19. 155(2):80-6. [Medline].

  • Sundh J, Stallberg B, Lisspers K, Montgomery SM, Janson C. Co-Morbidity, Body Mass Index and Quality of Life in COPD Using the Clinical COPD Questionnaire. COPD. 2011 Apr 22. [Medline].

  • McNamara D. Bronchiectasis Linked to Higher Mortality in COPD Patients. Medscape Medical News. February 8, 2013. [Full Text].

  • Martinez-Garcia MA, de la Rosa D, Soler-Cataluna JJ, Donat-Sanz Y, Catalan Serra P, Agramunt Lerma M, et al. Prognostic Value of Bronchiectasis in Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2013 Feb 7. [Medline].

  • [Guideline] Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011 Aug 2. 155(3):179-191. [Medline].

  • Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010 Sep 16. 363(12):1128-38. [Medline].

  • Casanova C, Cote C, Marin JM, Pinto-Plata V, de Torres JP, Aguirre-Jaime A, et al. Distance and oxygen desaturation during the 6-min walk test as predictors of long-term mortality in patients with COPD. Chest. 2008 Oct. 134(4):746-52. [Medline].

  • Spitzer C, Koch B, Grabe HJ, et al. Association of airflow limitation with trauma exposure and post-traumatic stress disorder. Eur Respir J. 2011 May. 37(5):1068-75. [Medline].

  • Singh B, Parsaik AK, Mielke MM, et al. Chronic obstructive pulmonary disease and association with mild cognitive impairment: the Mayo Clinic study of aging. Mayo Clin Proc. 2013 Nov. 88(11):1222-30. [Medline]. [Full Text].

  • Barclay L. COPD linked to cognitive impairment and memory loss. Medscape Medical News. December 12, 2013. [Full Text].

  • Prosen G, Klemen P, Strnad M, Grmec S. Combination of lung ultrasound (a comet-tail sign) and N-terminal pro-brain natriuretic peptide in differentiating acute heart failure from chronic obstructive pulmonary disease and asthma as cause of acute dyspnea in prehospital emergency setting. Crit Care. 2011. 15(2):R114. [Medline].

  • Sin DD, Miller BE, Duvoix A, et al. Serum PARC/CCL-18 Concentrations and Health Outcomes in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2011 May 1. 183(9):1187-1192. [Medline].

  • Osterweil N. COPD: Clinicians Miss Myriad Chances to Spot It Early. Medscape Medical News. Available at http://www.medscape.com/viewarticle/820597. Accessed: February 18, 2014.

  • Miller MR, Quanjer PH, Swanney MP, Ruppel G, Enright PL. Interpreting lung function data using 80% predicted and fixed thresholds misclassifies more than 20% of patients. Chest. 2011 Jan. 139(1):52-9. [Medline].

  • Rice KL, Dewan N, Bloomfield HE, Grill J, Schult TM, Nelson DB, et al. Disease management program for chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med. 2010 Oct 1. 182(7):890-6. [Medline].

  • Dewan NA, Rice KL, Caldwell M, Hilleman DE. Economic Evaluation of a Disease Management Program for Chronic Obstructive Pulmonary Disease. COPD. 2011 Apr 22. [Medline].

  • Stephenson A, Seitz D, Bell CM, et al. Inhaled anticholinergic drug therapy and the risk of acute urinary retention in chronic obstructive pulmonary disease: a population-based study. Arch Intern Med. 2011 May 23. 171(10):914-20. [Medline].

  • Gershon A, Croxford R, Calzavara A, To T, Stanbrook MB, Upshur R, et al. Cardiovascular Safety of Inhaled Long-Acting Bronchodilators in Individuals With Chronic Obstructive Pulmonary Disease. JAMA Intern Med. 2013 May 20. 1-9. [Medline].

  • Wood S. Inhaled Long-Acting Bronchodilators in COPD Flagged Again for CV Hazard. Medscape Medical News. Available at http://www.medscape.com/viewarticle/804441. Accessed: June 4, 2013.

  • Canavan N. Dual-Action Bronchodilator Eases COPD Exacerbations. Medscape [serial online]. Available at http://www.medscape.com/viewarticle/810739. Accessed: September 16, 2013.

  • Decramer ML, Chapman KR, Dahl R, et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. The Lancet Respiratory Medicine. Available at http://www.thelancet.com/journals/lanres/article/PIIS2213-2600(13)70158-9/abstract. Accessed: October 7, 2013.

  • Macfarlane L. Indacaterol and Tiotropium Similar in Effect and Safety. Medscape [serial online]. Available at http://www.medscape.com/viewarticle/811871. Accessed: October 7, 2013.

  • Mahler DA, Kerwin E, Ayers T, FowlerTaylor A, Maitra S, Thach C, et al. FLIGHT1 and FLIGHT2: Efficacy and Safety of QVA149 (Indacaterol/Glycopyrrolate) versus Its Monocomponents and Placebo in Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2015 Nov 1. 192 (9):1068-79. [Medline].

  • Rabe K, Martinez F, Rodriguez-Roisin R, Fabbri LM, Ferguson GT, Jones P, et al. PT003, a novel co-suspension MDI glycopyrronium/formoterol fixed-dose combination is superior to monocomponents in patients with COPD. Eur Respir J. 2015 Sep 01. 46(suppl 59):[Full Text].

  • US Food and Drug Administration. FDA approves Anoro Ellipta to treat chronic obstructive pulmonary disease [press release]. December 18, 2013. Available at http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm379057.htm. Accessed: December 30, 2013.

  • Brown T. FDA approves umeclidinium and vilanterol combo for COPD. Medscape Medical News. December 18, 2013. [Full Text].

  • Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med. 2013 Oct. 107(10):1538-46. [Medline].

  • Koch A, Pizzichini E, Hamilton A, Hart L, Korducki L, De Salvo MC. Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies. Int J Chron Obstruct Pulmon Dis

  • 1. Fan VS, Gaziano JM, Lew R, et al. A comprehensive care management program to prevent chronic obstructive pulmonary disease hospitalizationsa randomized, controlled trial. Ann Intern Med. 2012;156:673–683.[PubMed]

    2. Global Initiative for Chronic Obstructive Lung Disease (GOLD) [Accessed June 29, 2012];Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2011 http://www.goldcopd.org/

    3. American Thoracic Society and European Respiratory Society. [Accessed June 29, 2012];Standards for the diagnosis and management of patients with copd. 2004 http://www.thoracic.org/clinical/copd-guidelines/resources/copddoc.pdf.

    4. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26:948–968.[PubMed]

    5. Fragoso CAV, Concato J, McAvay G, Yaggi HK, Van Ness PH, Gill TM. Staging the severity of chronic obstructive pulmonary disease in older persons based on spirometric z-scores. J Am Geriatr Soc. 2011;59:1847–1854.[PMC free article][PubMed]

    6. Zvezdin B, Milutinov S, Kojicic M, et al. A postmortem analysis of major causes of early death in patients hospitalized with copd exacerbation. Chest. 2009;136:376–380.[PubMed]

    7. Morrison NJ, Richardson J, Dunn L, Pardy RL. Respiratory muscle performance in normal elderly subjects and patients with copd. Chest. 1989;95:90–94.[PubMed]

    8. Chatham K, Gelder CM, Lines TA, Cahalin LP. Suspected statin-induced respiratory muscle myopathy during long-term inspiratory muscle training in a patient with diaphragmatic paralysis. Phys Ther. 2009;89:257–266.[PubMed]

    9. Chan ED, Welsh CH. Geriatric respiratory medicine. Chest. 1998;114:1704–1733.[PubMed]

    10. Harrison RA, Siminoski K, Vethanayagam D, Majumdar SR. Osteoporosis-related kyphosis and impairments in pulmonary function: A systematic review. J Bone Miner Res. 2007;22:447–457.[PubMed]

    11. Vaz Fragoso CA, Gill TM. Respiratory impairment and the aging lung: A novel paradigm for assessing pulmonary function. J Gerontol Med Sci. 2012;67:264–275.[PMC free article][PubMed]

    12. Ats/accp statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2003;167:211–277.[PubMed]

    13. Casaburi R, ZuWallack R. Pulmonary rehabilitation for management of chronic obstructive pulmonary disease. New Engl J Med. 2009;360:1329–1335.[PubMed]

    14. Dyspnea Mechanisms, assessment, and management: A consensus statement. American thoracic society. Am J Respir Crit Care Med. 1999;159:321–340.[PubMed]

    15. Ries AL, Bauldoff GS, Carlin BW, et al. Pulmonary rehabilitation: Joint accp/aacvpr evidence-based clinical practice guidelines. Chest. 2007;131:4S–42S.[PubMed]

    16. ZuWallack R, Hedges H. Primary care of the patient with chronic obstructive pulmonary disease-part 3: Pulmonary rehabilitation and comprehensive care for the patient with chronic obstructive pulmonary disease. Am J Med. 2008;121:S25–32.[PubMed]

    17. O’Donnell DE. Breathlessness in patients with chronic airflow limitation. Mechanisms and management. Chest. 1994;106:904–912.[PubMed]

    18. Karapolat H, Eyigor S, Atasever A, Zoghi M, Nalbantgil S, Durmaz B. Effect of dyspnea and clinical variables on the quality of life and functional capacity in patients with chronic obstructive pulmonary disease and congestive heart failure. Chin Med J. 2008;121:592–596.[PubMed]

    19. Curtis JR, Martin DP, Martin TR. Patient-assessed health outcomes in chronic lung disease: What are they, how do they help us, and where do we go from here? Am J Respir Crit Care Med. 1997;156:1032–1039.[PubMed]

    20. Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: Accf/aha guidelines for the diagnosis and management of heart failure in adults: A report of the american college of cardiology foundation/american heart association task force on practice guidelines: Developed in collaboration with the international society for heart and lung transplantation. Circulation. 2009;119:1977–2016.[PubMed]

    21. Alonso-Coello P, Bellmunt S, McGorrian C, et al. Antithrombotic therapy in peripheral artery disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141:e669S–690S.[PMC free article][PubMed]

    22. Ioannidis JPA. Adverse events in randomized trials: Neglected, restricted, distorted, and silenced. Arch Intern Med. 2009;169:1737–1739.[PubMed]

    23. Vandenbroucke JP. What is the best evidence for determining harms of medical treatment? Can Med Assoc J. 2006;174:645–646.[PMC free article][PubMed]

    24. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis. Jama. 2008;300:1439–1450.[PubMed]

    25. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. New Engl J Med. 2008;359:1543–1554.[PubMed]

    26. Singh S, Furberg CD. Inhaled anticholinergics for chronic obstructive pulmonary disease: Comment on “inhaled anticholinergic drug therapy and the risk of acute urinary retention in chronic obstructive pulmonary disease. Arch Intern Med. 2011;171:920–922.[PubMed]

    27. Hordijk-Trion M, Lenzen M, Wijns W, et al. Patients enrolled in coronary intervention trials are not representative of patients in clinical practice: Results from the euro heart survey on coronary revascularization. European Heart Journal. 2006;27:671–678.[PubMed]

    28. Vandenbroucke JP, Psaty BM. Benefits and risks of drug treatments: How to combine the best evidence on benefits with the best data about adverse effects. JAMA. 2008;300:2417–2419.[PubMed]

    29. Stephenson A, Seitz D, Bell CM, et al. Inhaled anticholinergic drug therapy and the risk of acute urinary retention in chronic obstructive pulmonary disease: A population-based study. Arch Intern Med. 2011;171:914–920.[PubMed]

    30. Au DH, Udris EM, Fan VS, Curtis JR, McDonell MB, Fihn SD. Risk of mortality and heart failure exacerbations associated with inhaled beta-adrenoceptor agonists among patients with known left ventricular systolic dysfunction. Chest. 2003;123:1964–1969.[PubMed]

    31. Solano JP, Gomes B, Higginson IJ. A comparison of symptom prevalence in far advanced cancer, aids, heart disease, chronic obstructive pulmonary disease and renal disease. Journal of Pain & Symptom Management. 2006;31:58–69.[PubMed]

    32. Gore JM, Brophy CJ, Greenstone MA. How well do we care for patients with end stage chronic obstructive pulmonary disease (copd)? A comparison of palliative care and quality of life in copd and lung cancer. Thorax. 2000;55:1000–1006.[PMC free article][PubMed]

    33. Bausewein C, Booth S, Gysels M, Kuhnbach R, Haberland B, Higginson IJ. Understanding breathlessness: Cross-sectional comparison of symptom burden and palliative care needs in chronic obstructive pulmonary disease and cancer. Journal of Palliative Medicine. 2010;13:1109–1118.[PubMed]

    34. Claessens MT, Lynn J, Zhong Z, et al. Dying with lung cancer or chronic obstructive pulmonary disease: Insights from support. Study to understand prognoses and preferences for outcomes and risks of treatments. Journal of the American Geriatrics Society. 2000;48:S146–153.[PubMed]

    35. Lanken PN, Terry PB, Delisser HM, et al. An official american thoracic society clinical policy statement: Palliative care for patients with respiratory diseases and critical illnesses. Am J Respir Crit Care Med. 2008;177:912–927.[PubMed]

    36. Clemens KE, Faust M, Bruera E. Update on combined modalities for the management of breathlessness. Curr Opin Support Palliat Care. 2012;6:163–167.[PubMed]

    37. Johnson MJ, Abernethy AP, Currow DC. Gaps in the evidence base of opioids for refractory breathlessness. A future work plan? Journal of Pain & Symptom Management. 2012;43:614–624.[PubMed]

    38. Kamal AH, Maguire JM, Wheeler JL, Currow DC, Abernethy AP. Dyspnea review for the palliative care professional: Treatment goals and therapeutic options. Journal of Palliative Medicine. 2012;15:106–114.[PMC free article][PubMed]

    39. Rocker G, Young J, Donahue M, Farquhar M, Simpson C. Perspectives of patients, family caregivers and physicians about the use of opioids for refractory dyspnea in advanced chronic obstructive pulmonary disease. CMAJ. 2012;184:E497–E504.[PMC free article][PubMed]

    40. Katsura H, Kanemaru A, Yamada K, Motegi T, Wakabayashi R, Kida K. Long-term effectiveness of an inpatient pulmonary rehabilitation program for elderly copd patients: Comparison between young-elderly and old-elderly groups. Respirology. 2004;9:230–236.[PubMed]

    41. Baltzan MA, Kamel H, Alter A, Rotaple M, Wolkove N. Pulmonary rehabilitation improves functional capacity in patients 80 years of age or older. Canadian Respiratory Journal. 2004;11:407–413.[PubMed]

    42. Di Meo F, Pedone C, Lubich S, Pizzoli C, Traballesi M, Incalzi RA. Age does not hamper the response to pulmonary rehabilitation of copd patients. Age Ageing. 2008;37:530–535.[PubMed]

    43. Williams SJ, Bury MR. Impairment, disability and handicap in chronic respiratory illness. Social Science & Medicine. 1989;29:609–616.[PubMed]

    44. Saliba D, Elliott M, Rubenstein LZ, et al. The vulnerable elders survey: A tool for identifying vulnerable older people in the community. J Am Geriatr Soc. 2001;49:1691–1699.[PubMed]

    45. Eisner MD, Blanc PD, Yelin EH, et al. Copd as a systemic disease: Impact on physical functional limitations. Am J Med. 2008;121:789–796.[PMC free article][PubMed]

    46. Thakur N, Blanc PD, Julian LJ, et al. Copd and cognitive impairment: The role of hypoxemia and oxygen therapy. Int J Chron Obstruct Pulmon Dis. 2010;5:263–269.[PMC free article]

    0 thoughts on “73 Year Old Man C.E Case Study Emphysema

    Leave a Reply

    Your email address will not be published. Required fields are marked *